Nuvation Bio Inc. Payments for Restructuring
Nuvation Bio Inc. (NUVB) reported Payments for Restructuring of $7.39 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-15.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsForRestructuring · last filed 2023-03-15
- Nuvation Bio Inc. payments for restructuring for the quarter ending 2022-12-31 was $3.15M.
- Nuvation Bio Inc. payments for restructuring for fiscal 2022 was $7.39M.
| Period end | Payments for Restructuring 3 month | Payments for Restructuring 9 month | Payments for Restructuring 12 month |
|---|---|---|---|
| 2022-12-31 | $3.15M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $7.39M 10-K · filed 2023-03-15 | |
| 2022-09-30 | $4.25M 10-Q · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |